Furthermore, a review produced from database analysis found that breast and ovarian cancer share a high frequency of mutations in TP53, most of which are frameshift mutations [28], indicating that such mutations can serve as potential biomarkers for these types of cancer. This evidence concerns the gene TP53 and cancer.